Internal PC with Xilinx U280 FPGA board

Patho.Ai On Prem LLM Accelerator Z: Unleash Protein Drug Discovery Power

Uncover Faster Results

The Patho.Ai On Prem LLM Accelerator Z leverages a Large Language Model (LLM) and a Xilinx U280 FPGA PCI board to significantly accelerate protein drug discovery. The multi-agent architecture optimizes the process, leading to faster breakthroughs in medical research.

Xilinx U280 FPGA: Powering Patho.Ai On Prem LLM Accelerator Z

Multi-Agent Advantage

The Patho.Ai On Prem LLM Accelerator Z incorporates a multi-agent architecture, distributing tasks across multiple processing units. This parallel processing approach significantly reduces computation time, leading to faster protein drug discovery results.

Conclusion

The Patho.Ai On Prem LLM Accelerator Z delivers a powerful combination for accelerating protein drug discovery. With the Xilinx U280 FPGA at its core, researchers can unlock faster breakthroughs in the fight against disease.